<DOC>
	<DOCNO>NCT00223080</DOCNO>
	<brief_summary>The purpose study determine whether immunization integrate combination ALVAC-HIV ( vCP1521 ) boost AIDSVAX gp120 B/E prevent HIV infection healthy Thai volunteer .</brief_summary>
	<brief_title>HIV Vaccine Trial Thai Adults</brief_title>
	<detailed_description>A vaccine prevention HIV infection remain urgent need part effort control HIV pandemic . In phase III efficacy trial , 'prime-boost ' vaccine strategy evaluate prevention infection ameliorationn disease course . ALVAC-HIV ( vCP1521 ) sanofi pasteur give 'prime ' vaccine month 0 , 1 , 3 6 ; AIDSVAX gp120 B/E VaxGen give 'boost ' month 3 6 . This regimen give 8,000 adult Thai subject , another 8,000 give placebo double-blinded , randomized manner . Following completion subject immunization phase , he/she follow 3 year clinic visit every 6 month HIV test , pre- post-test counseling . Subjects become HIV infect counsel , refer HIV treatment facility management accord national guideline , offer enrollment protocol extend follow-up .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Thai citizen , 1830 year age ; either gender , Available participation 3.5 year , Able understand study give write informed consent , Completed enrollment associate screen protocol HIV positive , Participant previous HIV vaccine trial , Active TB systemic disease ; immunodeficiency chronic use immune modifying therapy , History anaphylaxis serious adverse reaction vaccine , For woman , breast feeding pregnant ( plan become pregnant first 9 month enrollment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>HIV Seronegativity</keyword>
</DOC>